Baxter International has submitted an MAA to the EMa for approval of Rixubis, recombinant factor IX (nonacog gamma) for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. The filing is based on results of research with hemophilia B patients previously treated with other therapies. Hemophilia B, also known as Christmas disease, is the second most common type of hemophilia and results from insufficient amounts of clotting factor IX, a naturally occurring protein ...